ABSTRACT
Objective To analyze the effect of Yishenkang capsule on urinary protein in patients with chronic glomerulonephritis uraemia. Methods 100 patients with chronic glomerulonephritis uraemia from March 2013 to April 2016 were divided into two groups with lottery method and 50 cases for each group. Two groups were treated with dialysis and routine treatment, the treatment group was added Yishenkang capsule to analyze its effect. Results After treatment, 24 h urinary protein of two groups decreased than before treatment, both Alb and Hb increased than before treatment, and the treatment group was better than that of the control group with statistical significance (P<0.05). SCr, BUN and UA level of two groups decreased than before treatment, the treatment group was lower than that of the control group with statistical significance (P<0.05). The level of inflammation in the control group was significantly higher than that before treatment, the treatment group decreased and lower than that of the control group with statistical significance (P<0.05). There were no significant differences in adverse reactions between two groups. Conclusion Yishenkang capsule could decrease the excretion of urine protein in patients with chronic nephritis uraemia, improve the renal function and has few adverse reactions.
ABSTRACT
Objective To analyze the effect of Yishenkang capsule on urinary protein in patients with chronic glomerulonephritis uraemia. Methods 100 patients with chronic glomerulonephritis uraemia from March 2013 to April 2016 were divided into two groups with lottery method and 50 cases for each group. Two groups were treated with dialysis and routine treatment, the treatment group was added Yishenkang capsule to analyze its effect. Results After treatment, 24 h urinary protein of two groups decreased than before treatment, both Alb and Hb increased than before treatment, and the treatment group was better than that of the control group with statistical significance (P<0.05). SCr, BUN and UA level of two groups decreased than before treatment, the treatment group was lower than that of the control group with statistical significance (P<0.05). The level of inflammation in the control group was significantly higher than that before treatment, the treatment group decreased and lower than that of the control group with statistical significance (P<0.05). There were no significant differences in adverse reactions between two groups. Conclusion Yishenkang capsule could decrease the excretion of urine protein in patients with chronic nephritis uraemia, improve the renal function and has few adverse reactions.